CoreMap, Inc. — SEC Form D Filing

CoreMap, Inc. filed an SEC Form D on June 24, 2026, reporting $35.51M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
June 24, 2026
Amount reported
$35.51M
Industry
Medical Devices
Website
https://coremapmedical.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Atrial fibrillation (AF) is an irregular heartbeat that can cause blood clots, stroke, and heart failure, affecting millions of patients. Current treatments for permanent and persistent AF are not universally effective for all patients.

Solution

CoreMap is developing advanced diagnostic technology, specifically ultra-high resolution electrodes, to allow physicians to visualize atrial fibrillation and enable patient-specific treatments for complex atrial arrhythmias.

Verdict

Investors backed this round because the technology offered a credible path to more effective treatment for a large, well-understood clinical problem, not because of a disruptive payment model. They were implicitly betting on a regulatory pathway that would validate the device's diagnostic superiority and translate directly into improved patient outcomes, justifying its premium. The upside was limited by the incremental nature of diagnostic improvement within an established treatment paradigm, rather than fundamentally changing how care is delivered.

Source: SEC EDGAR Form D filing